Xellia

Invested >$100m in R&D

Transformed from a supplier of niche active pharmaceutical ingredients to a fully-integrated speciality pharmaceutical company

Investment date

2008 - 2013

Good to great

money multiple

invested in R&D during investment

Successfully grew and transitioned the business to become a leader in the supply of key anti-infective products

EBITDA growth per annum

Invested more than $100m in R&D and capacity expansion across its global manufacturing network

Established a high-calibre management team through our Business Leaders Network

Platform created for continued growth and enhanced margins, based on a broadened product range and an exciting pipeline of new products

Xellia’s focus on R&D resulted in 15 new product ﬁlings in the year prior to our sale

Expanded Xellia's global manufacturing network including a ﬁll-ﬁnish plant in Copenhagen and a manufacturing plant in China to secure low-cost supply